Everest Medicines Balance Sheet Health
Financial Health criteria checks 6/6
Everest Medicines has a total shareholder equity of CN¥5.0B and total debt of CN¥480.6M, which brings its debt-to-equity ratio to 9.7%. Its total assets and total liabilities are CN¥5.8B and CN¥804.1M respectively.
Key information
9.7%
Debt to equity ratio
CN¥480.59m
Debt
| Interest coverage ratio | n/a |
| Cash | CN¥2.35b |
| Equity | CN¥4.97b |
| Total liabilities | CN¥804.10m |
| Total assets | CN¥5.77b |
Recent financial health updates
Recent updates
Does Everest Medicines (HKG:1952) Have A Healthy Balance Sheet?
Apr 27
Everest Medicines Limited (HKG:1952) Annual Results: Here's What Analysts Are Forecasting For This Year
Mar 31A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Jan 31A Look At The Fair Value Of Everest Medicines Limited (HKG:1952)
Sep 26Financial Position Analysis
Short Term Liabilities: 1952's short term assets (CN¥2.5B) exceed its short term liabilities (CN¥300.1M).
Long Term Liabilities: 1952's short term assets (CN¥2.5B) exceed its long term liabilities (CN¥504.0M).
Debt to Equity History and Analysis
Debt Level: 1952 has more cash than its total debt.
Reducing Debt: 1952 had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 1952 has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 1952 is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 12.4% per year.